Применение антиинфекционных препаратов у пациентов пожилого возраста | КМАХ

Применение антиинфекционных препаратов у пациентов пожилого возраста

Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(4):267-271

​ Ортенберг Э.А.
пожилые пациенты антимикробные препараты эффективность безопасность лекарственные взаимодействия
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(4):267-271

Аннотация

В данной статье описаны факторы, способствующие снижению эффективности антимикробных препаратов у пожилых пациентов, а также факторы и механизмы, снижающие безопасность этой группы препаратов. Подробно рассмотрены особенности применения различных групп антимикробных препаратов при инфекциях, наиболее часто встречающихся в пожилом возрасте, таких как инфекции дыхательных путей, инфекции мочевых путей и инфекции кожи и мягких тканей. Также представлены данные о лекарственных взаимодействиях между антимикробными препаратами и препаратами других групп, часто применяемыми в пожилом возрасте.

Ортенберг Эдуард Анатольевич

ГБОУ ВПО «Тюменский государственный медицинский университет» Минздрава России, Тюмень, Россия

  • 1. Cohen J.E. Human population: the next half century. Science 2003; 302:1172-5.
  • 2. Albert S., Schafer V., Brade V. Epidemiology and therapy of bacterial infections in geriatrics. Z Gerontol Geriatr 2000; 33:357-66.
  • 3. Gruver A., Hadson L., Semprowski G. Immunosenescence of ageing. J Pathol 2007; 211:144-56.
  • 4. Hakim F.T., Gress R.E. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens 2007; 70:179-89.
  • 5. Krokan H.E., Kavli B., Slupphaug G. Novel aspects of macromolecular repair and relationship to human disease. J Mol Med 2004; 82:280-97.
  • 6. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клиническая Микробиология и Антимикробная Химиотерапия 2005; 7(1):4-31.
  • 7. Garibaldi R.A. Residential care and the elderly: the burden of infection. J Hosp Infect 1999; 43(Suppl):9-18
  • 8. Gavazzi G., Krause K.H. Ageing and infection. Lancet Infect Dis 2002; 2(11):659-66.
  • 9. Nicolle L.E., Strausbaugh L.J., Garibaldi R.A. Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 1996; 9:1-17.
  • 10. Saner H. Cardiovascular system and aging. Ther Umsch 2005; 62:827-35.
  • 11. Faulkner C.M., Cox H.L., Williamson J.C. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 2005; 40:997-1004.
  • 12. Sherlock S., Bearn A.G., Billing B.H., Paterson J.C. Splanchnic blood flow in man by the bromsulfalein method: the relation of peripheral plasma bromsulfalein level to the calculated flow. J Lab Clin Med 1950; 35:923-32.
  • 13. Bonomo R.A. Resistant pathogens in respiratory tract infections in older people. J Am Geriatr Soc 2002; 50(7 Suppl):236-41.
  • 14. Marrie T.J. Community-acquired pneumonia requiring hospitalization. Is it different in the elderly? J Am Geriatr Soc 1985; 33:671-80.
  • 15. Gregoratos G. Infective endocarditis in the elderly: diagnosis and management. Am J Geriatr Cardiol 2003; 12:183-9.
  • 16. Inelmen E.M., Sergi G., Enzi G. When are indwelling urinary catheters appropriate in elderly patients? Geriatrics 2007; 62:18-22.
  • 17. Синопальников А.И., Андреева И.В., Стецюк О.У. Пневмонии в домах престарелых: современный взгляд на проблему. Клиническая Микробиология и Антимикробная Химиотерапия 2007; 9(1):4-19.
  • 18. Marques L.P., Flores J.T., de Barros O., et al. Epidemiological and clinical aspects of urinary tract infection in community-dwelling elderly women. Braz J Infect Dis 2012; 16(5):436-41.
  • 19. Siegel J.D., Rhinehart E., Jackson M., Chiarello L. Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006. Atlanta, GA: Centers for Disease Control and Prevention; 2006. [Accessed May 25, 2013]. Available from: http://www.cdc.gov/hicpac/pdf/guidelines/MDROGuideline2006.pdf.
  • 20. Ben-Ami R., Schwaber M.J., Navon-Venezia S., et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42:925-34.
  • 21. Pop-Vicas A., Tacconelli E., Gravenstein S., Lu B., D’Agata E.M. Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infect Control Hosp Epidemiol 2009; 30:325-31.
  • 22. Sersté T., Bourgeois N. Ageing and the liver. Acta Gastroenterol Belg 2006; 69:296-8.
  • 23. Rowe J.W., Andres R., Tobin J.D., et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31:155-63.
  • 24. Davies D.F., Shock N.W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29:496-507.
  • 25. Stahlmann R., Lode H.M. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013; 12(4):497-505.
  • 26. Ho J., Juurlink D. Considerations when prescribing trimethoprim-sulfamethoxazole CMAJ 2011; 183:1851-8.
  • 27. Peetermans W., Verbist L. Coagulation disorders caused by cephalosporins containing methylthiotetrazole side chains. Acta Clin Belg 1990; 45(5):327-33.
  • 28. Cusack B.J. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2:274-302.
  • 29. Hébuterne X. Gut changes attributed to ageing: effects on intestinal microflora. Curr Opin Clin Nutr Metab Care 2003; 6:49-54.
  • 30. Di Bella S., Capone A., Musso M., et al. Clostridium difficile infection in the elderly. Infez Med 2013; 21:93-102.
  • 31. Grill M.F., Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestsations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008; 42:1843-50.
  • 32. Chow K.M., Hui A.C., Szeto C.C. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24:649-53.
  • 33. Sugimoto M., Uchida I., Mashimo T., et al. Evidence for the involvement of GABA(A) receptor blockage in convulsions induced by cephalosporins. Neuropharmacology 2003; 45:304-14.
  • 34. Greenblatt D.J., Sellers E.M., Shader R.I. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306:1081-8.
  • 35. Shi S., Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011; 12:601-10.
  • 36. Cotter M. , Donlon S., Roche F., Byrne H., Fitzpatrick F. Healthcare-associated infection in Irish long-term care facilities: results from the First National Prevalence Study. J Hosp Infect 2012; 80:212-6.
  • 37. Curns A.T., Holman R.C., Sejvar J.J., et al. Infectious disease hospitalizations among older adults in the United States from 1990 through 2002. Arch Intern Med 2005; 165:2514-20.
  • 38. Liang S.Y., Mackowiak P.A. Infections in the elderly. Clin Geriatr Med 2007; 23:441-56.
  • 39. Werner H., Kuntsche J. Infection in the elderly-what is different? Z Gerontol Geriatr 2000; 33:350-6.
  • 40. Ferrara A., Fietta A. New developments in antibacterial choice for lower respiratory tract infections in elderly patients. Drugs Aging 2004; 21:167-86.
  • 41. Roede B.M., Bresser P., El Moussaoui R., et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin Microbiol Infect 2007; 13:284-90.
  • 42. Andriole V.T., Haverstock D.C., Choudhri S.H. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28:443-52.
  • 43. Neralla S., Meyer K. Drug treatment of pneumococcal pneumonia in the elderly Drugs Aging 2004; 21:851-64.
  • 44. Van den Brande P., Van Stennbergen W., Vervoort G., et al. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152:1705-8.
  • 45. Smith N.M. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 2006; 55(RR-10):1-42.
  • 46. Das R., Perrelli E., Towle V., et al. Antimicrobial susceptibility of bacteria isolated from urine samples obtained from nursing home residents. Infect Control Hosp Epidemiol 2009; 30(11):1116-9.
  • 47. Takahashi P., Trang N., Chutka D., Evans J. Antibiotic prescribing and outcomes following treatment of symptomatic urinary tract infections in older women. J Am Med Dir Assoc 2004; 5(2 Suppl): S11-5.
  • 48. Finn J.C., Flicker L., Mackenzie E., et al. Interface between residential aged care facilities and a teaching hospital emergency department in Western Australia. Med J Aust 2006; 184:432-5.
  • 49. Boockvar K.S., Gruber-Baldini A.L., Burton L., Zimmerman S., May C., Magaziner J. Outcomes of infection in nursing home residents with and without early hospital transfer. J Am Geriatr Soc 2005; 53(4):590-6.
  • 50. Washio M., Kiyohara C., Hamada T,. et al. The case fatality rate of methicillin-resistant Staphylococcus aureus (MRSA) infection among the elderly in a geriatric hospital and their risk factors. The Tohoku Journal of Experimental Medicine 1997; 183:75-82.
  • 51. Lim C., Kong D., Stuart R. Reducing inappropriate antibiotic prescribing in the residential care setting: current perspectives Clin Interv Aging 2014; 9:165-77.
  • 52. McClean P., Hughes C., Tunney M., Goossens H., Jans B. European Surveillance of Antimicrobial Consumption (ESAC) Nursing Home Project Group Antimicrobial prescribing in European nursing homes. J Antimicrob Chemother 2011; 66:1609-16.
  • 53. Howard P.A. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacother 2013; 47:1547-51.
  • 54. Ray W.A., Murray K.T., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089-96.
  • 55. Shakeri-Nejad K., Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7(6):639-51.
  • 56. Mills K., Graham A.C., Winslow B.T., Springer K.L. Treatment of nursing home-acquired pneumonia. Am Fam Physician 2009; 79(11):976-82.
  • 57. Dumyati G., Falsey A.R. Antivirals for influenza: what is their role in the older patient? Drugs Aging 2002; 19:777-86.
  • 58. Guay D.R.P. Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. Drugs Aging 1994; 5:8-19.
  • 59. Obez C., Barisic A.M., Chatelier W., et al. The computerassisted management programs for antibiotic therapies in connection with an application in geriatrics. Pathol Biol 2004; 52:589-96.
  • 60. Naughton B.J., Mylotte J.M. Treatment guideline for nursing home-acquired pneumonia based on community practice. J Am Geriatr Soc 2000; 48(1):82-8.
  • 61. Sicras M.A., Pelaez L.J. Improving adequacy for drug use and effects in geriatric centers using an intervention program. Farm Hosp 2005; 29(5):303-11.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились